Perspective from a Principal Investigator - aGVHD

Dr Ashleigh Scott, Principal Investigator at Royal Brisbane and Women's Hospital, discusses Cynata's Phase 2 clinical trial evaluating CYP-001 for acute graft-versus-host disease (aGvHD) - a life-threatening complication of bone marrow transplantation.

In this interview, Dr Scott explains what makes aGvHD such a serious condition, why current treatment options are often inadequate for high-risk patients, and how the trial is designed to evaluate whether CYP-001 - an iPSC-derived mesenchymal stem cell therapy - can improve outcomes when combined with standard steroid treatment.

The trial enrolled 65 patients across multiple centres in Australia, the United States, and Europe, and is now in the evaluation period with results expected around June 2026. Dr Scott walks through the challenges of conducting trials in rare conditions, what the primary endpoints measure, and how a successful outcome could transform the treatment landscape for patients facing this devastating complication.